Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methotrexate (Intravenous Administration) Clear all
Completed Phase 2 Interventional

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

NCT00313625
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, melphalan, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Results available

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

NCT00634504
View directory record Official record
Conditions
Osteosarcoma, Leukemia, Lymphoma
Interventions
glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
Drug
Lead sponsor
BTG International Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Little Rock, Arkansas • El Cajon, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

NCT00045305
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 28, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)

NCT00396812
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

NCT00020943
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
80
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067
View directory record Official record
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

NCT00499889
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate, Fludarabine (Fludara), Busulfan, Antithymocyte Globulin (ATG), Tacrolimus, Methotrexate, Donor lymphocyte infusion (DLI), Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 28, 2026, 10:13 AM EDT
Withdrawn Phase 4 Interventional

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

NCT05494593
View directory record Official record
Conditions
Mucopolysaccharidosis (MPS), Hunter Syndrome
Interventions
ELAPRASE, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 6 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Oakland, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00098774
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cytarabine, etoposide, leucovorin calcium, methotrexate, temozolomide
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
30
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 28, 2026, 10:13 AM EDT
Withdrawn Phase 4 Interventional

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115
View directory record Official record
Conditions
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions
interferon beta 1a, methotrexate, methylprednisolone
Drug
Lead sponsor
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 28, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

NCT01483690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 28, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

NCT02097745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
methotrexate, rituximab [MabThera/Rituxan]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
59
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

NCT01345682
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
Afatinib, Methotrexate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 28, 2026, 10:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696
View directory record Official record
Conditions
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

NCT01382940
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

NCT06475235
View directory record Official record
Conditions
Lymphoma, Primary Central Nervous System Lymphoma
Interventions
Pembrolizumab, Methotrexate, Temozolomide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

NCT00267865
View directory record Official record
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

NCT02440464
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 28, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

NCT07768436
View directory record Official record
Conditions
Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
Interventions
CMF Regimen, Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 28, 2026, 10:13 AM EDT